A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).
AuteursYau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Peña A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
AuteursRobert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, Brandao M, Korakis I, Rouge TM, Comis S, Imadalou K, Chevalier C, Cordonnier L, Josse C, Teppaz G, Seité M, Durand J, Thepenier V, Mary C, Gauttier V, Derame M, Morello A, Poirier N, Cassier PA
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis.
AuteursVan Melkebeke L, Boesch M, Ostyn T, Huang W, Akkaya C, van Sligtenhorst M, El Abyad D, Safaeifard F, Dumarey A, Wallays M, Boeckx B, Feio-Azevedo R, Smets L, Gustot T, Trepo E, Moreno C, Putignano A, Lasser L, Colle I, Deltenre P, Marot A, Topal B, Claus E, Bonne L, Maleux G, Scheele C, Hendrikx T, Nevens F, Korf H, Roskams T, Denadai-Souza A, Lambrechts D, Govaere O, Van der Merwe S, Verbeek J
